Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2018 - 2026)

Ocular Therapeutix has reported Total Non-Current Liabilities over the past 11 years, most recently at $150.0 million for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 7.29% year-over-year to $150.0 million; the TTM value through Mar 2026 reached $150.0 million, up 7.29%, while the annual FY2025 figure was $139.8 million, 1.83% down from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $150.0 million at Ocular Therapeutix, up from $139.8 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $150.0 million in Q1 2026 and troughed at $94.6 million in Q1 2022.
  • A 5-year average of $124.1 million and a median of $130.9 million in 2023 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 42.07% in 2023 and later dropped 3.43% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $107.6 million in 2022, then grew by 21.74% to $130.9 million in 2023, then increased by 8.79% to $142.4 million in 2024, then decreased by 1.83% to $139.8 million in 2025, then grew by 7.3% to $150.0 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for OCUL at $150.0 million in Q1 2026, $139.8 million in Q4 2025, and $137.7 million in Q3 2025.